发布求助
文献互助 智能选刊 最新文献

Clinical Advances in Hematology & Oncology最新文献

筛选
英文 中文
Highlights in metastatic prostate cancer from the European Society for Medical Oncology Congress 2024. 欧洲肿瘤内科学会 2024 年大会的转移性前列腺癌亮点。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-10-01
{"title":"Highlights in metastatic prostate cancer from the European Society for Medical Oncology Congress 2024.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 6 8","pages":"1-20"},"PeriodicalIF":1.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management options for node-positive muscle-invasive bladder cancer. 结节阳性肌肉浸润性膀胱癌的治疗方案。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-10-01
Hyma V Polimera, Priyanka Bhatia, Megan Wheelden, Stuthi Perimbeti, Joshua Warrick, Monika Joshi
{"title":"Management options for node-positive muscle-invasive bladder cancer.","authors":"Hyma V Polimera, Priyanka Bhatia, Megan Wheelden, Stuthi Perimbeti, Joshua Warrick, Monika Joshi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Localized node-positive bladder cancer is characterized by a high degree of heterogeneity, leading to significant variability in overall survival outcomes among affected individuals. The absence of standardized treatment guidelines presents a critical challenge in managing these patients effectively. This comprehensive review article delves into the pathophysiology, clinical significance, and management of node-positive bladder cancer. It critically evaluates the current therapeutic landscape and explores emerging treatment strategies, including novel drugs currently undergoing clinical trials. By synthesizing the latest research findings, the review aims to provide valuable insights into the optimal management of node-positive urothelial cell carcinoma, ultimately contributing to improved patient outcomes and quality of life.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 8","pages":"392-402"},"PeriodicalIF":1.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights in metastatic prostate cancer from the European Society for Medical Oncology Congress 2024: commentary. 欧洲肿瘤内科学会 2024 年大会转移性前列腺癌亮点：评论。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-10-01
Pedro C Barata
{"title":"Highlights in metastatic prostate cancer from the European Society for Medical Oncology Congress 2024: commentary.","authors":"Pedro C Barata","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 6 8","pages":"7-17"},"PeriodicalIF":1.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can unresectable non-small cell lung cancer become resectable? 无法切除的非小细胞肺癌可以切除吗？
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-07-01
Jamie E Chaft
{"title":"Can unresectable non-small cell lung cancer become resectable?","authors":"Jamie E Chaft","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 6","pages":"261-262"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on CDK4/6 inhibitors in breast cancer. 乳腺癌 CDK4/6 抑制剂的最新进展。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-07-01
Sara M Tolaney
{"title":"Update on CDK4/6 inhibitors in breast cancer.","authors":"Sara M Tolaney","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 6","pages":"298-300"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancer. 问与答：检测转移性肺癌和甲状腺癌中 NTRK 融合的障碍。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-07-01
David S Hong, Alexander Drilon, Lori J Wirth
{"title":"Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancer.","authors":"David S Hong, Alexander Drilon, Lori J Wirth","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 5 6","pages":"16"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of patients with NTRK fusion-positive lung cancer. NTRK 融合阳性肺癌患者的管理。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-07-01
Alexander Drilon
{"title":"Management of patients with NTRK fusion-positive lung cancer.","authors":"Alexander Drilon","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 5 6","pages":"5-9"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. NTRK 抑制剂对 NTRK 融合阳性肺癌和甲状腺癌患者的疗效和安全性。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-07-01
David S Hong, Alexander Drilon, Lori J Wirth
{"title":"Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers.","authors":"David S Hong, Alexander Drilon, Lori J Wirth","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are implicated in various cancers, including those of the lung and thyroid. The prevalence of NTRK fusions is 0.1 to 0.3% in non-small cell lung cancer (NSCLC) and as high as 26% in pediatric papillary thyroid carcinoma. Detection methods include immunohistochemistry, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, and next-generation sequencing. Management of NTRK fusion-positive lung cancer primarily involves targeted therapies, notably the tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib. Both agents demonstrate high response rates and durable disease control, particularly in metastatic adenocarcinoma of the lung. They are preferred as first-line treatments because of their efficacy over immunotherapy. Possible adverse events include dizziness, weight gain, neuropathy-like pain, and liver enzyme elevation. Larotrectinib and entrectinib also produce robust and durable responses in NTRK fusion-positive thyroid cancer that is refractory to radioactive iodine. Second-generation TRK inhibitors that have been designed to overcome acquired resistance are under investigation.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 5 6","pages":"1-20"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. 批准在慢性淋巴细胞白血病中使用 lisocabtagene maraleucel。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-07-01
William G Wierda
{"title":"The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia.","authors":"William G Wierda","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 6","pages":"291-293"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of patients with NTRK fusion-positive thyroid cancer. 对NTRK融合阳性甲状腺癌患者的治疗。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-07-01
Lori J Wirth
{"title":"Management of patients with NTRK fusion-positive thyroid cancer.","authors":"Lori J Wirth","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 Suppl 5 6","pages":"9-15"},"PeriodicalIF":1.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信